Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

about

Tocilizumab: A Review in Rheumatoid Arthritis.[Lymphoma in rheumatic diseases].A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

P2860

Q43280791-E6C43244-C99F-4D46-A1E4-A5F2A984EFE5 Q50057583-253AB630-D4DF-440F-8758-E9989D2FF8A8 Q52675492-A3479D4E-20E4-47CD-A92C-77D3EDFC995F

P2860

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

Item

http://www.wikidata.org/entity/Q36919914

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

@en

type

Item

label

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

@en

prefLabel

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

@en

P1476

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

@en

P2093

Andrea Rubbert-Roth

http://www.w3.org/2001/XMLSchema#string

Anthony Sebba

http://www.w3.org/2001/XMLSchema#string

Ariella Kelman

http://www.w3.org/2001/XMLSchema#string

Benjamin Porter-Brown

http://www.w3.org/2001/XMLSchema#string

Jennifer Pulley

http://www.w3.org/2001/XMLSchema#string

Laura Brockwell

http://www.w3.org/2001/XMLSchema#string

Pavel Napalkov

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

P304

e000213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2015-000213

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Rubbert-Roth

Ronald van Vollenhoven

P577

2016-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27252893

http://www.w3.org/2001/XMLSchema#string

P932

4874056

http://www.w3.org/2001/XMLSchema#string

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

about

P2860

P2860

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932